Growth Metrics

Zevra Therapeutics (ZVRA) Cash from Investing Activities (2018 - 2025)

Zevra Therapeutics' Cash from Investing Activities history spans 11 years, with the latest figure at $227000.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 104.15% year-over-year to $227000.0; the TTM value through Dec 2025 reached $18.1 million, up 181.8%, while the annual FY2025 figure was $18.1 million, 181.8% up from the prior year.
  • Cash from Investing Activities reached $227000.0 in Q4 2025 per ZVRA's latest filing, up from -$4.6 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $34.0 million in Q2 2023 to a low of -$44.5 million in Q3 2023.
  • Average Cash from Investing Activities over 5 years is -$3.9 million, with a median of -$81000.0 recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: crashed 59280.77% in 2021, then surged 16901.59% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$15.4 million in 2021, then soared by 99.59% to -$63000.0 in 2022, then soared by 16901.59% to $10.6 million in 2023, then crashed by 151.69% to -$5.5 million in 2024, then soared by 104.15% to $227000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Cash from Investing Activities are $227000.0 (Q4 2025), -$4.6 million (Q3 2025), and $11.9 million (Q2 2025).